The Chinese STEMI PPCI Registry (CSPR)

Completed

• Conditions: ST-segment Elevation Myocardial Infarction (STEMI)
• Interventions: Other: no intervention

• Registration Number: NCT04996901
• Lead Sponsor: Renmin Hospital of Wuhan University

Brief Summary

The purpose of this study is to develop a risk score to predict the risks of in-hospital major adverse cardiac events in ST-segment elevation myocardial infarction patients treated by primary percutaneous coronary intervention.

Detailed Description

The CSPR trial is an observational clinical trial to derive and validate a readily useable risk score to identify patients at high risk of in-hospital major adverse cardiac events in 5594 patients presenting with a ST-segment elevation myocardial infarction and treated by primary percutaneous coronary intervention.

Study Timeline

• Study Start: 2021-05-22
• Study First Submitted: 2021-07-27
• Study First Submitted QC: 2021-08-06
• Study First Posted: 2021-08-09
• Status Verified: 2021-12
• Primary Completion: 2021-12-05
• Study Completion: 2021-12-05
• Last Update Submitted: 2021-12-09
• Last Update Posted: 2021-12-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 5594

Inclusion Criteria

1. Age≥18
2. ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction
3. STEMI treated by pPCI

Exclusion Criteria

1. Patient with heart failure in admission
2. STEMI with symptom-onset-to-balloon time>24h
3. pPCI was not successful or only underwent coronary angiography
4. Killip class ≥II in admission

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
derivation cohort	no intervention	Data from Renmin Hospital of Wuhan University, The First College of Clinical Medical Science, China Three Gorges University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Xiangyang No.1 People's Hospital，and Wuhan Third Hospital will be used as a derivation cohort.
validation cohort	no intervention	Data from The First Affiliated Hospital of Dalian Medical University and Jiangxi Provincial People's Hopital will be used as a derivation cohort.

Primary Outcome Measures

Name	Time	Method
in-hospital acute de novo heart failure	in-hospital outcome, until discharge	Killip class ≥II
cardiogenic shock	in-hospital outcome, until discharge	according to the universal definition
death	in-hospital outcome, until discharge	according to the universal definition

Trial Locations

Locations (1)

Renmin Hospital of Wuhan university; 🇨🇳 Wuhan, Hubei, China